Immunology
Variant-resistant COVID-19 vaccines could be effective, cheap to make
Researchers have collaborated to create a new COVID-19 vaccine platform containing antigens against the fusion protein of the SARS-CoV-2 virus that could be effective against variants of the virus. The research was published online on April 15 in the Proceedings of the National Academy of Sciences. Read More
Will preprints have a lasting effect on publishing beyond COVID-19?
During the COVID-19 pandemic, 25% of all COVID-19-related scientific manuscripts were shared on preprint servers, a steep increase from previous usage and relative to traditional peer-review journals. An international team of researchers explored the critical role of preprint servers in disseminating epidemic-related information in an article published in PLOS Biology on April 2. Read More
What pregnant women need to know about COVID vaccines
Addressing questions about COVID-19 vaccines for pregnant and postpartum women, a leading maternal-fetal medicine specialist explained that it's likely best to get vaccinated as soon as they are eligible. Read More
Can a single dose of a vaccine designed as 2 doses be effective?
Researchers suggested that two doses of a COVID-19 vaccine are more protective than a single dose, even if the interdose period is longer than recommended. The study's results, published in Science on March 9, indicate that the effect of vaccines on the spread and mutation of SARS-CoV-2 is reliant on relative robustness of immunity conferred by a single dose. Read More
Chromatography drives research fight against SARS-CoV-2 virus
As the battle against the deadly SARS-CoV-2 virus continues, researchers are relying on analytical laboratory techniques like chromatography to provide effective and efficient methods for characterizing the virus, as well as to analyze potential vaccines and anti-COVID-19 compounds. Read More
Janssen COVID-19 vaccine becomes 3rd authorized in U.S.
Janssen Biotech's COVID-19 vaccine has received an emergency use authorization from the U.S. Food and Drug Administration. The move allows the vaccine to be distributed in the U.S. for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age or older. Read More
FDA committee gives nod to Janssen COVID-19 vaccine
A single-shot COVID-19 vaccine from Johnson & Johnson's Janssen Biotech subsidiary has received a positive recommendation from a U.S. Food and Drug Administration (FDA) advisory committee. Should the FDA grant the product emergency use authorization, the vaccine candidate will become the third to be made available in the U.S. Read More
New open-access toolkit helps research labs study SARS-CoV-2
One of the most important factors in fighting the COVID-19 pandemic is large-scale scientific collaborations and knowledge sharing. One international group of researchers has made its simple, robust toolkit available to laboratories around the globe that are unaccustomed to working with coronaviruses. The details can be found in a PLOS Biology paper published on February 25. Read More
Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many biopharmaceutical companies are continuing to push new vaccine candidates toward regulatory approval. The slow rollout of approved vaccines has created the need for second-generation products with the potential to accelerate the world's return to something approaching normalcy. Read More
The next generation of COVID-19 vaccines: Gallo on next steps
What will the next generation of COVID-19 vaccines look like? In the first of a two-part series, The Science Advisory Board spoke with pioneering virology researcher Dr. Robert Gallo to get his thoughts on what a next-generation COVID-19 vaccine might look like, and which candidates are in the running for marketing authorization. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter